- Author(s):
- Organization(s):
Merck
Pursuing inhaled therapies offers opportunities for changing route of administration, expanding indications, adopting fixed dose combinations and developing different formulation/device combinations.
Pulmonary delivery formulation and development require a commitment similar to that of a new product. Yet the clinical benefits and strong resistance of inhaled products to brand erosion can make pulmonary administration very attractive for product life management.